Chiara Sabatini


I had received the Master’s degree of Pharmacy in the 2005 from the University of Milano investigating the activity of δ-CaMKII in fibroblasts from Alzheimer disease’ patients under the supervision of prof. M. Popoli and prof.G. Racagni in the Department of Pharmacological Sciences and Center of Excellence on Neurodegenerative Diseases.

I joined Rottapharmbiotech in the 2007 as scientist in the Biochemical Laboratory in the Pharmacology and Toxicology Department. I am involving in in vitro research, screening small molecules or biologics toward several targets (e.g. soluble and receptor kinases, proteases, channel receptors) spanning different fields (e.g. osteoarthritis disease and rheumatoid arthritis, pain, HIV).

In order to enhance my expertise and the educational background, I engaged in the Executive PhD path, focusing my research in the Neuroscience field.


Study of CR4056 interactions with the opioid system: deepen the molecular mechanism for new perspective in the pain management.

Track: Experimental Neuroscience

Tutor: Gianfranco Caselli

CR4056 is a first-in-class imidazoline-2 binding site ligand with potent analgesic activity in different animal models of inflammatory, postoperative, fibromyalgia-like, neurogenic, neuropathic and osteoarthritis pain. Recently, its analgesic efficacy has been proved in a Phase IIa clinical study in patients with osteoarthritis of the knee with moderate to severe chronic pain. Therefore, CR4056 is the first I2 ligand whose analgesic efficacy has been demonstrated in humans.

Moreover, in line with the well known interaction between I2 ligands and the opioid system, CR4056 showed a robust synergy with morphine in neurogenic and post-surgical models of pain.

The purpose of this project is to investigate the relationship between CR4056  and the opioid system deepening the molecular mechanism.




Further details are available here: